Double-Blind, Randomized Trial to Investigate the Antihypertensive and Metabolic Effects of Candesartan in Insulin-Resistant Obese Patients With a Hypertension Not Adequately Controlled by Previous beta-Blocker or Calcium Channel Blocker.
Phase of Trial: Phase IV
Latest Information Update: 11 Aug 2013
At a glance
- Drugs Candesartan cilexetil; Hydrochlorothiazide
- Indications Hypertension
- Focus Therapeutic Use
- Sponsors Takeda Pharma
- 10 Jun 2017 Biomarkers information updated
- 07 Aug 2012 Actual patient number changed from 180 to 188 as reported by ClinicalTrials.gov.
- 12 Jul 2011 New source identified and integrated (European Clinical Trials Database record).